Clinical Trial: De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07153757) titled 'De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial' on Aug. 26.

Brief Summary: This study is a prospective, randomized, open-label, non-inferiority Phase III clinical trial, planning to enroll 2,934 patients, with a 1:1 allocation to either the conventional endocrine therapy group or the de-escalation therapy group. The aim is to evaluate the safety and efficacy of 2-3 years of de-escalated endocrine therapy in patients with T1N0M0 potentially low-risk breast cancer, respectively.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Breast Cancer Early Stage Breast Cancer (Stage 1-3)...